Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab clinical benefit verification study in early Alzheimer's disease
jRCT2021220027Phase 4Suspended
- Sponsor
- Biogen
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Aduhelm 10 mg/kg with Placebo (2 arms). Primary endpoint: Change from baseline in CDR-SB score. Started Dec 2022; status: suspended.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2021220027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220027.